ProCE Banner Activity

Expert Perspectives With FLT3-Mutated AML Testing and Treatment: Challenges and Opportunities

Clinical Thought

Read this commentary by leading AML experts on what you need to know for providing high-quality care for patients with FLT3-mutated AML, including their thoughts on optimal testing for FLT3 mutations, use of available FLT3 inhibitors, and promising new directions in treatment.

Released: April 30, 2025

Expiration: April 29, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.

Disclosure

Primary Author

Harry P. Erba, MD, PhD: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Glycomimetics, Incyte, Jazz, Kura Oncology, Pfizer, Servier, Stemline, Sumitomo Pharma, Syndax; researcher (paid to institution): Aptos, MacroGenics.

Eunice S. Wang, MD: consultant/advisor/speaker: AbbVie, Astellas, Blueprint, Daiichi Sankyo, Dark Blue, Dava Oncology, GlaxoSmithKline, Kite, Kura, Novartis, Qiagen, Rigel, Ryvu, Schrodinger, Servier, Stemline, Syndax, Pfizer, Takeda; data and safety monitoring: AbbVie.